Drug Trial Radar · NCT07504458
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jun 8, 2026
Primary completion
Mar 2027
Study completion Dec 2030
Sponsor
- Lead sponsor
- Quetzal TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 71 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.
Conditions
- Acute Promyelocytic Leukemia (APL)
- Acute Promyelocytic Leukaemia
- Acute Promyelocytic Leukemia With PML-RARA
- Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
- Acute Promyelocytic Leukemia
Interventions
QTX-2101 + ATRADrug
The experimental regimen consists of IV ATO administered once daily during induction, given continuously, for up to a maximum of 60 days. During consolidation, QTX-2101 is administered once daily, per investigator's protocol. ATRA is administered orally in two divided daily doses during induction, given continuously until bone marrow remission (not exceeding 60 days). During consolidation, ATRA is taken orally in two divided daily doses following a 2-weeks-on / 2-weeks-off schedule within each 8-week cycle.
IV arsenic trioxide (ATO) + ATRADrug
The comparator regimen consists of IV ATO administered once daily during induction, given continuously, for up to a maximum of 60 days. During consolidation, IV ATO is administered once daily, per investigator's protocol. ATRA is administered orally in two divided daily doses during induction, given continuously until bone marrow remission (not exceeding 60 days). During consolidation, ATRA is taken orally in two divided daily doses following a 2-weeks-on / 2-weeks-off schedule within each 8-week cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma (concentration (Cmax) of QTX-2101 for ASIIITime frame: Up to 1 cycle of consolidation therapy (each cycle is 8 weeks)
- Molecular complete remission (molecular CR) rateTime frame: Up to 60 days of induction and 3 8-week cycles of consolidation treatment
Locations
39 sites in 5 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham (UAB)
Birmingham, Alabama · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
University of California, Irvine
Irvine, California · Recruiting
USC Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
UCI Health - UCI Medical Center
Orange, California · Recruiting
Stanford University School of Medicine
Stanford, California · Recruiting
Colorado Blood Cancer Institute
Denver, Colorado · Recruiting
Emory Winship Cancer Institute
Atlanta, Georgia · Recruiting
Augusta University Medical Center
Augusta, Georgia · Recruiting
University of Kentucky Markey Cancer Center
Lexington, Kentucky · Recruiting
University of Maryland Medical Center
Baltimore, Maryland · Recruiting
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
The Ohio State University Wexner Medical Center
Columbus, Ohio · Recruiting
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania · Recruiting
Sarah Cannon Research Institute at TriStar Centennial Medical Center
Nashville, Tennessee · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Virginia Health
Charlottesville, Virginia · Recruiting
Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Sud, Centre François Magendie
Bordeaux, France · Recruiting
CHU Grenoble Alpes - Hôpital Michallon
La Tronche, France · Recruiting
Centre Hospitalier Régional Universitaire (CHRU) de Nancy - Hôpitaux de Brabois
Nancy, France · Recruiting
Centre Hospitalier Universitaire (CHU) de Nice - Hôpital de l'Archet 1
Nice, France · Recruiting
Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis
Paris, France · Recruiting
Centre Hospitalier Universitaire (CHU) de Saint-Étienne - Hôpital Nord
Saint-Priest-en-Jarez, France · Recruiting
Hôpitaux Universitaires de Strasbourg
Strasbourg, France · Recruiting
Hospital Tor Vergata Roma
Roma, Italy · Recruiting
Azienda ULSS 8 Berica - Ospedale San Bortolo
Vicenza, Italy · Recruiting
Institutul Oncologic "Prof. Dr. Ion Chiricuță"
Cluj-Napoca, Romania · Recruiting
Institut Català d'Oncologia (ICO) Badalona - Hospital Universitari Germans Trias i Pujol
Badalona, Spain · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain · Recruiting
Hospital Universitario San Pedro de Alcántara
Cáceres, Spain · Recruiting
Hospital Regional Universitario de Málaga
Málaga, Spain · Recruiting
Hospital Universitario Central de Asturias
Oviedo, Spain · Recruiting
Hospital Universitario y Politécnico La Fe
Valencia, Spain · Recruiting
Hospital Universitari Son Espases
Palma de Mallorca, Balearic Islands, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.